What is the appropriate dosage, indications, contraindications, and follow‑up for Polymyxin B ophthalmic solution?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Polymyxin B Ophthalmic Solution

Indications

Polymyxin B ophthalmic solution (combined with trimethoprim) is FDA-approved for treating surface ocular bacterial infections, specifically acute bacterial conjunctivitis and blepharoconjunctivitis caused by susceptible organisms 1. The covered pathogens include Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae, and Pseudomonas aeruginosa 1.

Clinical Context for Use

  • Mild bacterial conjunctivitis: Polymyxin B/trimethoprim is an appropriate first-line empiric choice, particularly when cost is a consideration 2
  • The combination provides broad-spectrum coverage against both gram-positive (trimethoprim) and gram-negative organisms (polymyxin B) 1
  • Clinical studies demonstrate 95% cure or improvement rates within 7 days in pediatric populations 3

Dosage

Standard dosing: 1 drop four times daily for 7 days 4

Important Dosing Considerations

  • The formulation contains 10,000 units polymyxin B and 1 mg trimethoprim per mL 1
  • Peak serum concentrations after instillation are minimal (0.03 mcg/mL trimethoprim, 1 unit/mL polymyxin B at 20 minutes to 3 hours), indicating primarily local action 1
  • For moderate to severe bacterial conjunctivitis with copious purulent discharge, pain, and marked inflammation, consider fluoroquinolones or fortified antibiotics instead 2

Comparative Efficacy Note

While polymyxin B/trimethoprim remains effective, moxifloxacin 0.5% three times daily achieves faster symptom resolution (81% complete resolution at 48 hours vs 44% with polymyxin B/trimethoprim) 4. However, by day 7-10, clinical cure rates are equivalent (96% for polymyxin B/trimethoprim vs 95% for moxifloxacin) 5, making polymyxin B/trimethoprim a cost-effective alternative when rapid resolution is not critical.

Contraindications

Absolute contraindication: Known hypersensitivity to polymyxin B, trimethoprim, or any component of the formulation 1

Additional Clinical Cautions

  • Avoid in patients with suspected viral conjunctivitis (adenoviral, HSV) where antibiotics provide no benefit and may cause adverse effects 2
  • Not appropriate for gonococcal conjunctivitis, which requires systemic antibiotic therapy 2
  • Should not be used for bacterial keratitis as primary therapy—topical fluoroquinolones or fortified antibiotics are preferred for corneal involvement 6

Follow-Up

Instruct patients to return in 3-4 days if no improvement is noted 2

Structured Follow-Up Algorithm

If improved at 3-4 days:

  • Continue treatment to complete 7-day course
  • No additional follow-up needed unless symptoms recur

If no improvement or worsening at 3-4 days:

  • Perform interval history, visual acuity measurement, and slit-lamp biomicroscopy 2
  • Obtain conjunctival cultures and Gram stain 2
  • Consider switching to fluoroquinolone or fortified antibiotics
  • Evaluate for alternative diagnoses (viral, allergic, or resistant organisms)

If corneal involvement develops:

  • Immediate re-evaluation required
  • Switch to bacterial keratitis treatment protocol with fluoroquinolones or fortified antibiotics 6

Special Populations

Pediatric patients: Polymyxin B/trimethoprim demonstrates excellent efficacy and tolerability, with 95% cure rates and minimal adverse events 3. The same dosing and follow-up apply.

Contact lens wearers: If conjunctivitis develops with contact lens use, discontinue lens wear immediately and ensure coverage for Pseudomonas (polymyxin B component provides this) 6

Key Clinical Pitfalls

  • Do not use for membranous conjunctivitis or severe disease with marked chemosis/eyelid swelling—these require more aggressive therapy and possible corticosteroids 2
  • Avoid patching the eye in contact lens-associated cases due to increased risk of secondary bacterial keratitis 6
  • Do not prescribe for prophylaxis without documented bacterial infection
  • Recognize treatment failure early—if no improvement by day 3-4, culture and switch therapy rather than extending ineffective treatment 2

References

Related Questions

What is the appropriate dose of polymyxin B ophthalmic solution (0.1% concentration) for a child weighing 30 pounds?
What is the appropriate dose of polymyxin B ophthalmic solution eye drops for a 4-year-old child?
What is the appropriate dosing schedule for a 1 mg/mL polymyxin B/trimethoprim ophthalmic solution?
What is the appropriate dose of polymyxin B otic solution for a child weighing 49 pounds?
What is the recommended dosing regimen of polymyxin B/trimethoprim ophthalmic solution for patients aged two months and older?
In a 6-year-old with anxiety and habitual finger‑picking who is taking Adderall immediate‑release (amphetamine/dextroamphetamine) 10 mg daily and guanfacine (Tenex) 1 mg daily, how should the medication regimen be adjusted to address the persistent anxiety?
Should I continue oral terbinafine for another course in a patient with severe tinea capitis who has had major improvement after 6 weeks but still has residual disease?
What is the differential diagnosis for a 10-year-old boy with two months of daily nausea and occasional late‑day vomiting?
What is the appropriate management for a 15-year-old with left facial nerve palsy presenting with facial swelling, numbness, incomplete smile, and limited ability to puff out the cheek?
What are the mechanisms of action of peptides in dermatologic skincare?
What are the possible causes of new-onset headache, dizziness, and foggy vision in the right eye in a 65-year-old patient?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.